Literature DB >> 12359126

Coenzyme Q(10) and idebenone in the therapy of respiratory chain diseases: rationale and comparative benefits.

Vanna Geromel1, Niklas Darin, Dominique Chrétien, Paule Bénit, Pascale DeLonlay, Agnès Rötig, Arnold Munnich, Pierre Rustin.   

Abstract

While there have been major advances in both the identification of the molecular basis and our understanding of mitochondrial pathology, the clinical management of patients with mitochondrial respiratory chain disease is still essentially supportive. Quinones are the only pharmacological agents that have proven some efficacy when, and only when, given to patients presenting with quite specific respiratory chain defects. In this article, after a short presentation of the coenzyme Q(10) molecule, its origin and distribution in human body, we summarize our present knowledge on its several physiological functions. We next discuss the rational that justifies using different types of quinones in the therapy of mitochondrial disorders. We finally briefly review the available data obtained in the therapy of mitochondrial disorders by using quinones as either substitutive electron carriers or antioxidant compounds.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12359126     DOI: 10.1016/s1096-7192(02)00145-2

Source DB:  PubMed          Journal:  Mol Genet Metab        ISSN: 1096-7192            Impact factor:   4.797


  38 in total

Review 1.  Mitochondrial medicine: to a new era of gene therapy for mitochondrial DNA mutations.

Authors:  Hélène Cwerman-Thibault; José-Alain Sahel; Marisol Corral-Debrinski
Journal:  J Inherit Metab Dis       Date:  2010-06-23       Impact factor: 4.982

Review 2.  Mitochondrial energetics and therapeutics.

Authors:  Douglas C Wallace; Weiwei Fan; Vincent Procaccio
Journal:  Annu Rev Pathol       Date:  2010       Impact factor: 23.472

3.  Why are there no proven therapies for genetic mitochondrial diseases?

Authors:  Peter W Stacpoole
Journal:  Mitochondrion       Date:  2011-05-13       Impact factor: 4.160

4.  Dietary supplementation of some antioxidants against hypoxia.

Authors:  Sanaa Ahmed Ali; Hanan Farouk Aly; Lilla Mohammed Faddah; Zeenat F Zaidi
Journal:  World J Gastroenterol       Date:  2012-11-28       Impact factor: 5.742

5.  Design and implementation of the first randomized controlled trial of coenzyme CoQ₁₀ in children with primary mitochondrial diseases.

Authors:  Peter W Stacpoole; Ton J deGrauw; Annette S Feigenbaum; Charles Hoppel; Douglas S Kerr; Shawn E McCandless; Michael V Miles; Brian H Robinson; Peter H Tang
Journal:  Mitochondrion       Date:  2012-09-25       Impact factor: 4.160

6.  Pathomechanisms in coenzyme q10-deficient human fibroblasts.

Authors:  Luis C López; Marta Luna-Sánchez; Laura García-Corzo; Catarina M Quinzii; Michio Hirano
Journal:  Mol Syndromol       Date:  2014-07

Review 7.  Therapeutic Approaches to Treat Mitochondrial Diseases: "One-Size-Fits-All" and "Precision Medicine" Strategies.

Authors:  Emanuela Bottani; Costanza Lamperti; Alessandro Prigione; Valeria Tiranti; Nicola Persico; Dario Brunetti
Journal:  Pharmaceutics       Date:  2020-11-11       Impact factor: 6.321

8.  Treatment of CoQ(10) deficient fibroblasts with ubiquinone, CoQ analogs, and vitamin C: time- and compound-dependent effects.

Authors:  Luis C López; Catarina M Quinzii; Estela Area; Ali Naini; Shamima Rahman; Markus Schuelke; Leonardo Salviati; Salvatore Dimauro; Michio Hirano
Journal:  PLoS One       Date:  2010-07-30       Impact factor: 3.240

Review 9.  Endogenous synthesis of coenzyme Q in eukaryotes.

Authors:  UyenPhuong C Tran; Catherine F Clarke
Journal:  Mitochondrion       Date:  2007-03-30       Impact factor: 4.160

Review 10.  Mitochondrial oxidative phosphorylation: pitfalls and tips in measuring and interpreting enzyme activities.

Authors:  D Chretien; P Rustin
Journal:  J Inherit Metab Dis       Date:  2003       Impact factor: 4.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.